According to IQVIA statistics, the global IVD market expanded 6% LC in 2023, continuing to show a rebound from the COVID period.

The 2024 annual reports of major Chinese IVD companies released.

PrediLife said recently that it has signed on the Institut Curie to perform the genetic analysis portion of its MammoRisk breast cancer risk assay.

On May 20, 2019, Thermo Fisher Scientific announced that it is investing more than $50 million into its global bioproduction capabilities. The expansion will provide additional capacity for manufacturing single-use bioprocess container (BPC)

Velano Vascular has secured $10 million as the initial tranche of a growth financing to fuel commercialization and the launch of new vascular access solutions. But perhaps most telling about this funding news is the notable investors who kic

Schaffhausen, Switzerland-based Physeon is trying to bring its Veinplicity device to the U.S. market. The device is designed to make veins easier to access on the first stick, preventing patients from being treated as pincushions.

Atellica Solution Immunoassay Clinical Chemistry Analyzers Atellica Solution is a multi analyzer system for in vitro diagnostic testing of clinical specimens. It offers unprecedented flexibility with over 300 configurations. Components can

Point-of-care (POC) testing is a rapidly growing market. As healthcare starts to shift toward consumers, the demand for tests that can be performed anywhere the patient is located, is increasing. With the promise to reduce costs and give qui

A November 2018 FDA inspection has resulted in a warning letter for Zeller Power Products. The Wallace, ID-based company makes a replacement battery for Cardiac Science's PowerHeart Automated External Defibrillator (AED) G3.

Robotics in medtech are quickly becoming common place as the number of companies in the market continue to grow. On June 12, seasoned veterans of robotic surgery companies will share their thoughts about the state of surgical robotics techno

Grail has hit a major milestone as the liquid biopsy company is reporting it has been granted Break Through Device Designation by FDA. The Menlo Park, CA-based company is developing an investigational next-generation sequencing (NGS) blood t

Illumina and the Childrens Hospital of Fudan University in China plan to launch a study of whole-genome sequencing in the hospitals neonatal intensive care unit to determine whether it can be used as a diagnostic for critically ill infants,